SRK Family

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by the transforming growth factor beta (TGF-beta) superfamily of growth factors plays a fundamental role. The company's proprietary platform is designed to target the latent forms of growth factors, allowing for highly specific modulation of growth factor signaling. Its lead product candidate, apitegromab (SRK-015), is a selective inhibitor of myostatin activation being developed for spinal muscular atrophy (SMA). Additionally, the company is advancing SRK-181 for the treatment of solid tumors and exploring programs in cardiometabolic diseases such as obesity.